Reply to the Response from Babette Wolf et al. to our Letter to the Editor: How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response

Cytokine

Volumn 64, Issue 1, 2013, Pages 476-

  Thorpe, Susan J ^a   Stebbings, Richard ^a   Findlay, Lucy ^a   Eastwood, David ^a   Poole, Stephen ^a   Thorpe, Robin ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; TGN 1412;

ASSAY; BLOOD ANALYSIS; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; HUMAN; LETTER; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; WHOLE BLOOD ASSAY;

EID: 84883559046     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.07.013     Document Type: Letter

References (3)

1. Findlay L., Eastwood D., Ball C., Robinson C.J., Bird C., Wadhwa M., et al. Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. J Immunol Methods 2011, 371:134-142.
2. Wolf B., Morgan H., Krieg J., Gani Z., Milicov A., Warncke M., et al. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans. Cytokine 2012, 60:828-837.
3. Eastwood D, Bird C, Dilger P, Hockley J, Findlay L, Poole S, et al. Lessons learned from TGN1412 trial failure: the severity of TGN1412-associated 'cytokine storm' correlates with IL-2 release. Brit J Clin Pharmacol 2013; May 23, doi: 10.1111/bcp.12165 [Epub ahead of print].